S&P 500   3,461.29 (+0.53%)
DOW   28,405.40 (+0.34%)
QQQ   285.91 (+0.53%)
AAPL   117.74 (+0.20%)
MSFT   214.76 (+0.05%)
FB   279.24 (+4.37%)
GOOGL   1,598.00 (+4.45%)
AMZN   3,225.00 (+0.25%)
TSLA   428.85 (+1.64%)
NVDA   546.29 (+0.09%)
BABA   311.42 (+0.52%)
CGC   20.07 (+6.30%)
GE   7.31 (-0.41%)
MU   53.32 (-0.39%)
AMD   81.09 (-0.58%)
T   26.61 (-0.56%)
F   7.78 (+0.52%)
ACB   4.88 (+7.02%)
GILD   60.20 (-0.61%)
NFLX   500.56 (-4.73%)
BA   165.84 (-0.84%)
BAC   24.21 (+0.29%)
DIS   124.70 (-0.20%)
S&P 500   3,461.29 (+0.53%)
DOW   28,405.40 (+0.34%)
QQQ   285.91 (+0.53%)
AAPL   117.74 (+0.20%)
MSFT   214.76 (+0.05%)
FB   279.24 (+4.37%)
GOOGL   1,598.00 (+4.45%)
AMZN   3,225.00 (+0.25%)
TSLA   428.85 (+1.64%)
NVDA   546.29 (+0.09%)
BABA   311.42 (+0.52%)
CGC   20.07 (+6.30%)
GE   7.31 (-0.41%)
MU   53.32 (-0.39%)
AMD   81.09 (-0.58%)
T   26.61 (-0.56%)
F   7.78 (+0.52%)
ACB   4.88 (+7.02%)
GILD   60.20 (-0.61%)
NFLX   500.56 (-4.73%)
BA   165.84 (-0.84%)
BAC   24.21 (+0.29%)
DIS   124.70 (-0.20%)
S&P 500   3,461.29 (+0.53%)
DOW   28,405.40 (+0.34%)
QQQ   285.91 (+0.53%)
AAPL   117.74 (+0.20%)
MSFT   214.76 (+0.05%)
FB   279.24 (+4.37%)
GOOGL   1,598.00 (+4.45%)
AMZN   3,225.00 (+0.25%)
TSLA   428.85 (+1.64%)
NVDA   546.29 (+0.09%)
BABA   311.42 (+0.52%)
CGC   20.07 (+6.30%)
GE   7.31 (-0.41%)
MU   53.32 (-0.39%)
AMD   81.09 (-0.58%)
T   26.61 (-0.56%)
F   7.78 (+0.52%)
ACB   4.88 (+7.02%)
GILD   60.20 (-0.61%)
NFLX   500.56 (-4.73%)
BA   165.84 (-0.84%)
BAC   24.21 (+0.29%)
DIS   124.70 (-0.20%)
S&P 500   3,461.29 (+0.53%)
DOW   28,405.40 (+0.34%)
QQQ   285.91 (+0.53%)
AAPL   117.74 (+0.20%)
MSFT   214.76 (+0.05%)
FB   279.24 (+4.37%)
GOOGL   1,598.00 (+4.45%)
AMZN   3,225.00 (+0.25%)
TSLA   428.85 (+1.64%)
NVDA   546.29 (+0.09%)
BABA   311.42 (+0.52%)
CGC   20.07 (+6.30%)
GE   7.31 (-0.41%)
MU   53.32 (-0.39%)
AMD   81.09 (-0.58%)
T   26.61 (-0.56%)
F   7.78 (+0.52%)
ACB   4.88 (+7.02%)
GILD   60.20 (-0.61%)
NFLX   500.56 (-4.73%)
BA   165.84 (-0.84%)
BAC   24.21 (+0.29%)
DIS   124.70 (-0.20%)
Log in
NASDAQ:TNDM

Tandem Diabetes Care Competitors

$116.75
+0.01 (+0.01 %)
(As of 10/21/2020 09:33 AM ET)
Add
Compare
Today's Range
$116.75
Now: $116.75
$118.25
50-Day Range
$105.32
MA: $111.39
$121.75
52-Week Range
$43.69
Now: $116.75
$123.74
Volume28 shs
Average Volume1.17 million shs
Market Capitalization$7.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.5

Competitors

Tandem Diabetes Care (NASDAQ:TNDM) Vs. RMD, TFX, PODD, NVCR, ABMD, and PEN

Should you be buying TNDM stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Tandem Diabetes Care, including ResMed (RMD), Teleflex (TFX), Insulet (PODD), Novocure (NVCR), ABIOMED (ABMD), and Penumbra (PEN).

ResMed (NYSE:RMD) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

69.4% of ResMed shares are owned by institutional investors. 1.2% of ResMed shares are owned by company insiders. Comparatively, 6.0% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

ResMed has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.

Profitability

This table compares ResMed and Tandem Diabetes Care's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ResMed21.02%30.34%15.73%
Tandem Diabetes Care-10.29%-12.88%-6.83%

Valuation and Earnings

This table compares ResMed and Tandem Diabetes Care's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$2.96 billion8.82$621.67 million$4.7637.80
Tandem Diabetes Care$362.30 million19.63$-24,750,000.00($0.22)-530.68

ResMed has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for ResMed and Tandem Diabetes Care, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ResMed36201.91
Tandem Diabetes Care041002.71

ResMed currently has a consensus price target of $186.6667, indicating a potential upside of 3.74%. Tandem Diabetes Care has a consensus price target of $113.8571, indicating a potential downside of 2.48%. Given ResMed's higher possible upside, equities analysts plainly believe ResMed is more favorable than Tandem Diabetes Care.

Summary

ResMed beats Tandem Diabetes Care on 9 of the 14 factors compared between the two stocks.

Teleflex (NYSE:TFX) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

91.3% of Teleflex shares are owned by institutional investors. 2.2% of Teleflex shares are owned by company insiders. Comparatively, 6.0% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Teleflex has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Tandem Diabetes Care has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.

Profitability

This table compares Teleflex and Tandem Diabetes Care's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teleflex18.99%17.15%7.91%
Tandem Diabetes Care-10.29%-12.88%-6.83%

Valuation and Earnings

This table compares Teleflex and Tandem Diabetes Care's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teleflex$2.60 billion6.48$461.47 million$11.1532.45
Tandem Diabetes Care$362.30 million19.63$-24,750,000.00($0.22)-530.68

Teleflex has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Teleflex and Tandem Diabetes Care, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teleflex01902.90
Tandem Diabetes Care041002.71

Teleflex currently has a consensus price target of $389.40, indicating a potential upside of 7.63%. Tandem Diabetes Care has a consensus price target of $113.8571, indicating a potential downside of 2.48%. Given Teleflex's stronger consensus rating and higher possible upside, equities analysts plainly believe Teleflex is more favorable than Tandem Diabetes Care.

Summary

Teleflex beats Tandem Diabetes Care on 11 of the 14 factors compared between the two stocks.

Insulet (NASDAQ:PODD) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Risk and Volatility

Insulet has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.

Profitability

This table compares Insulet and Tandem Diabetes Care's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Insulet2.20%10.96%1.81%
Tandem Diabetes Care-10.29%-12.88%-6.83%

Valuation and Earnings

This table compares Insulet and Tandem Diabetes Care's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insulet$738.20 million21.86$11.60 million$0.191,293.84
Tandem Diabetes Care$362.30 million19.63$-24,750,000.00($0.22)-530.68

Insulet has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Insulet and Tandem Diabetes Care, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Insulet110802.37
Tandem Diabetes Care041002.71

Insulet currently has a consensus price target of $223.8824, indicating a potential downside of 8.93%. Tandem Diabetes Care has a consensus price target of $113.8571, indicating a potential downside of 2.48%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than Insulet.

Summary

Insulet beats Tandem Diabetes Care on 9 of the 12 factors compared between the two stocks.

Novocure (NASDAQ:NVCR) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Novocure and Tandem Diabetes Care's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novocure2.88%5.14%2.41%
Tandem Diabetes Care-10.29%-12.88%-6.83%

Valuation and Earnings

This table compares Novocure and Tandem Diabetes Care's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novocure$351.32 million37.97$-7,230,000.00($0.07)-1,884.86
Tandem Diabetes Care$362.30 million19.63$-24,750,000.00($0.22)-530.68

Novocure has higher earnings, but lower revenue than Tandem Diabetes Care. Novocure is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Novocure and Tandem Diabetes Care, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novocure15402.30
Tandem Diabetes Care041002.71

Novocure currently has a consensus price target of $90.6667, indicating a potential downside of 31.28%. Tandem Diabetes Care has a consensus price target of $113.8571, indicating a potential downside of 2.48%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than Novocure.

Volatility & Risk

Novocure has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.

Insider and Institutional Ownership

67.6% of Novocure shares are owned by institutional investors. 5.1% of Novocure shares are owned by company insiders. Comparatively, 6.0% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Novocure beats Tandem Diabetes Care on 9 of the 14 factors compared between the two stocks.

Tandem Diabetes Care (NASDAQ:TNDM) and ABIOMED (NASDAQ:ABMD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Tandem Diabetes Care and ABIOMED's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tandem Diabetes Care-10.29%-12.88%-6.83%
ABIOMED19.88%16.17%14.21%

Valuation & Earnings

This table compares Tandem Diabetes Care and ABIOMED's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$362.30 million19.63$-24,750,000.00($0.22)-530.68
ABIOMED$840.88 million14.88$203.01 million$4.7458.60

ABIOMED has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than ABIOMED, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Tandem Diabetes Care and ABIOMED, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tandem Diabetes Care041002.71
ABIOMED13302.29

Tandem Diabetes Care presently has a consensus target price of $113.8571, indicating a potential downside of 2.48%. ABIOMED has a consensus target price of $223.00, indicating a potential downside of 19.65%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, research analysts clearly believe Tandem Diabetes Care is more favorable than ABIOMED.

Volatility & Risk

Tandem Diabetes Care has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, ABIOMED has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.

Insider & Institutional Ownership

94.9% of ABIOMED shares are owned by institutional investors. 6.0% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 3.4% of ABIOMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

ABIOMED beats Tandem Diabetes Care on 9 of the 14 factors compared between the two stocks.

Tandem Diabetes Care (NASDAQ:TNDM) and Penumbra (NYSE:PEN) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

84.0% of Penumbra shares are held by institutional investors. 6.0% of Tandem Diabetes Care shares are held by company insiders. Comparatively, 8.9% of Penumbra shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Tandem Diabetes Care and Penumbra, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tandem Diabetes Care041002.71
Penumbra02602.75

Tandem Diabetes Care presently has a consensus target price of $113.8571, indicating a potential downside of 2.48%. Penumbra has a consensus target price of $232.8333, indicating a potential upside of 9.53%. Given Penumbra's stronger consensus rating and higher possible upside, analysts clearly believe Penumbra is more favorable than Tandem Diabetes Care.

Profitability

This table compares Tandem Diabetes Care and Penumbra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tandem Diabetes Care-10.29%-12.88%-6.83%
Penumbra2.02%1.25%0.95%

Earnings and Valuation

This table compares Tandem Diabetes Care and Penumbra's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$362.30 million19.63$-24,750,000.00($0.22)-530.68
Penumbra$547.41 million14.02$48.46 million$0.98216.92

Penumbra has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Tandem Diabetes Care has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Summary

Penumbra beats Tandem Diabetes Care on 12 of the 14 factors compared between the two stocks.


Tandem Diabetes Care Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ResMed logo
RMD
ResMed
1.6$179.94+0.3%$26.00 billion$2.96 billion42.14Insider Selling
Teleflex logo
TFX
Teleflex
1.5$361.80+0.0%$16.83 billion$2.60 billion35.61
Insulet logo
PODD
Insulet
1.4$245.83+1.1%$16.14 billion$738.20 million878.00Decrease in Short Interest
Novocure logo
NVCR
Novocure
1.5$131.94+0.3%$13.34 billion$351.32 million1,099.59
ABIOMED logo
ABMD
ABIOMED
1.2$277.76+0.1%$12.50 billion$840.88 million80.05Increase in Short Interest
Penumbra logo
PEN
Penumbra
1.6$212.58+0.4%$7.68 billion$547.41 million733.06Upcoming Earnings
Increase in Short Interest
Irhythm Technologies logo
IRTC
Irhythm Technologies
1.2$223.10+3.6%$6.44 billion$214.55 million-89.96Analyst Downgrade
Hill-Rom logo
HRC
Hill-Rom
2.1$87.94+0.4%$5.88 billion$2.91 billion28.37
Globus Medical logo
GMED
Globus Medical
1.8$53.81+1.8%$5.25 billion$785.37 million62.57Upcoming Earnings
Analyst Report
Increase in Short Interest
Nevro logo
NVRO
Nevro
1.2$155.00+2.9%$5.17 billion$390.26 million-51.50
Haemonetics logo
HAE
Haemonetics
1.5$97.11+2.7%$4.79 billion$988.48 million52.49
Integra Lifesciences logo
IART
Integra Lifesciences
1.5$47.75+0.1%$4.02 billion$1.52 billion-1,591.67Upcoming Earnings
Increase in Short Interest
ICU Medical logo
ICUI
ICU Medical
1.3$190.35+0.6%$3.99 billion$1.27 billion49.31Decrease in Short Interest
Heavy News Reporting
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.0$122.76+1.0%$3.29 billion$82.05 million-54.08Increase in Short Interest
NuVasive logo
NUVA
NuVasive
1.6$52.74+0.6%$2.69 billion$1.17 billion-439.50Analyst Report
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.8$47.07+0.4%$2.61 billion$994.85 million-87.17Upcoming Earnings
SWAV
ShockWave Medical
1.1$73.50+0.7%$2.52 billion$42.93 million-35.00Analyst Report
Insider Selling
Glaukos logo
GKOS
Glaukos
0.9$55.74+1.3%$2.50 billion$236.98 million-33.38
SILK
Silk Road Medical
0.9$63.24+2.3%$2.13 billion$63.35 million-54.05Increase in Short Interest
Cantel Medical logo
CMD
Cantel Medical
1.7$47.72+2.3%$2.01 billion$1.02 billion116.39
AXNX
Axonics Modulation Technologies
1.4$46.94+0.0%$1.86 billion$13.82 million-17.98
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
0.8$10.87+1.2%$1.84 billion$4.11 million-6.32
AtriCure logo
ATRC
AtriCure
1.6$38.75+0.1%$1.74 billion$230.81 million-30.04Increase in Short Interest
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.3$38.24+0.3%$1.53 billion$236.54 million-49.03Analyst Revision
Atrion logo
ATRI
Atrion
1.0$653.00+0.4%$1.19 billion$155.07 million34.46
Cerus logo
CERS
Cerus
1.4$6.39+0.5%$1.07 billion$74.65 million-14.52
OraSure Technologies logo
OSUR
OraSure Technologies
1.3$14.69+0.5%$1.06 billion$154.60 million-489.50
Luminex logo
LMNX
Luminex
1.8$21.01+1.8%$991.71 million$334.64 million91.35Analyst Downgrade
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.3$47.66+0.8%$931.71 million$72.55 million-34.54
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.6$11.41+0.8%$810.92 million$88.02 million-20.37Upcoming Earnings
VAPO
Vapotherm
1.9$29.64+2.2%$774.77 million$48.10 million-13.12Increase in Short Interest
CryoLife logo
CRY
CryoLife
2.2$18.67+0.0%$706.81 million$276.22 million-62.23
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.4$36.08+0.2%$700.42 million$189.49 million-80.18
SIBN
SI-Bone
1.3$22.89+0.4%$652.76 million$67.30 million-13.23Insider Selling
Increase in Short Interest
Heavy News Reporting
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$33.67+1.1%$650.77 million$459.95 million-28.53Upcoming Earnings
Analyst Report
Heavy News Reporting
Alphatec logo
ATEC
Alphatec
1.4$10.06+0.6%$645.55 million$113.43 million-8.98Analyst Report
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.6$31.80+0.9%$643.22 million$117.23 million39.26
Surmodics logo
SRDX
Surmodics
1.4$41.29+1.4%$561.79 million$100.08 million73.73Increase in Short Interest
Antares Pharma logo
ATRS
Antares Pharma
1.8$3.15+0.6%$519.87 million$123.86 million78.77Decrease in Short Interest
Intersect ENT logo
XENT
Intersect ENT
1.5$15.81+2.7%$516.86 million$109.14 million-8.27
RCEL
AVITA MED LTD/S
1.3$23.87+0.8%$514.45 million$14.26 million-11.53
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.7$36.13+4.7%$513.30 million$114.51 million58.27Upcoming Earnings
AngioDynamics logo
ANGO
AngioDynamics
2.3$11.05+1.8%$419.38 million$264.16 million-2.49
SeaSpine logo
SPNE
SeaSpine
1.3$15.11+0.9%$412.28 million$159.08 million-7.79Analyst Report
Co-Diagnostics logo
CODX
Co-Diagnostics
1.4$13.25+0.4%$373.50 million$220,000.0073.61Decrease in Short Interest
Cytosorbents logo
CTSO
Cytosorbents
1.5$8.37+2.6%$361.23 million$24.95 million-16.10
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.4$13.81+0.0%$348.18 millionN/A-5.93
Utah Medical Products logo
UTMD
Utah Medical Products
0.8$83.98+1.5%$305.94 million$46.90 million24.99Upcoming Earnings
Heavy News Reporting
UFP Technologies logo
UFPT
UFP Technologies
1.3$39.40+0.3%$295.30 million$198.38 million16.77Heavy News Reporting
Accuray logo
ARAY
Accuray
1.5$3.17+2.5%$288.64 million$382.93 million105.50Increase in Short Interest
This page was last updated on 10/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.